NCT01435902撤回3 期
A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects With Exercise-Induced Bronchoconstriction
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Maximal percent decrease from baseline in FEV1 following exercise challenge at 12 hours post-dose
研究概览
简要总结
The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced by exercise compared with fluticasone propionate 250 mcg twice daily in adolescent and adult subjects aged 12 to 50 diagnosed with persistent asthma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 50 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatient male or female 12 to 50 years of age
- •Females of child-bearing potential must be willing to use birth control or commit to abstinence during the study
- •Diagnosis of persistent asthma for at least 6 months
- •Best pre-bronchodilator FEV1 of at least 70%.
- •Current use of a low- to moderate-dose inhaled corticosteroid
- •Ability to withhold albuterol 6 hours prior to visits.
- •Physically able to perform exercise testing on a treadmill when albuterol has been withheld
排除标准
- •Intermittent asthma, seasonal asthma, or exercise-induced asthma only
- •Symptomatic allergic rhinitis and/or thrush
- •Abnormal, clinically significant electrocardigraph
- •Respiratory infection within 4 weeks of first visit leading to asthma medication change or could affect subjects's asthma status or participation
- •Asthma exacerbation within 12 weeks of first visit
- •Respiratory diseases or other concurrent disease that would put subject at risk or confound results interpretation
- •Investigational medicines within 30 days of first visit or less than five half-lives of medication in prior study
- •Allergy to study drugs or study drug excipients
- •Concomitant medications that could interact with study medications or affect the course of asthma
- •Tobacco use within last year and/or a 10 pack-years history
- •Inability to comply with requirements of the study
- •Affiliation with investigator's site (example: family member)
研究组 & 干预措施
Fluticasone Furoate/Vilanterol
Active Comparator
Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
干预措施: Fluticasone Furoate/Vilanterol Inhalation Powder (Drug)
Fluticasone Propionate
Active Comparator
Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
干预措施: Fluticasone Propionate Inhalation Powder (Drug)
结局指标
主要结局
Maximal percent decrease from baseline in FEV1 following exercise challenge at 12 hours post-dose
时间窗: At the end of treatment Week 4
次要结局
- Maximal percent decrease from baseline in FEV1 following exercise challenge at 1 hour and 23 hours post-dose(At the end of treatment Week 4)
- Time required for recovery to within 5% of the pre-exercise baseline FEV1 from the time of the maximal percentage decrease from baseline following the challenge at 1 hour, 12 hours, and 23 hours post-dose(At the end of treatment Week 4)
- AUC (0-60 minutes) for percentage decrease from baseline in FEV1 after exercise at 1 hour, 12 hours, and 23 hours post-dose(At the end of treatment Week 4)
- Evaluation of a categorical treatment response using the percentage of subjects who demonstrate a decrease from the pre-exercise baseline in FEV1 of 1) <10%, 2) 10 to <20%, and 3) =/>20%.(At the end of treatment Week 4)
- Maximal percent decrease from pre-randomized treatment baseline in FEV1 following exercise challenge at 1 hour, 12 hours, and 23 hours post-dose.(At the end of treatment Week 4)
研究者
相似试验
进行中（未招募）
3 期
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsAsthmaNCT06052267Teva Branded Pharmaceutical Products R&D LLC2,772
已完成
3 期
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With AsthmaAsthmaNCT02502734GlaxoSmithKline60
已完成
4 期
Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate AsthmaAsthmaNCT00830505University of Dundee38
已完成
4 期
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00361959GlaxoSmithKline1,270
已完成
3 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic RhinitisRhinitis, Allergic, PerennialAllergic RhinitisNCT01231464GlaxoSmithKline365